

# Edwards PASCAL Transcatheter Valve Repair System

## MiCLASP Post-Market Study: 1-Year Outcomes




Professor Lurz reported the 1-year outcomes of the single-arm, multi-centre MiCLASP post-market clinical follow-up (PMCF) study.

### Study design & baseline parameters<sup>1</sup>

Study design: prospective, single arm, multi-centre study		
Enrolled patients: 500	Male: 59%	Age, years (mean): 77 ± 10
NYHA functional class III or IV: 77%	STS score (MV repair): 5.1% ± 4.3	Euroscore II: 7.6% ± 7.5
MR etiology: Functional 64%, degenerative 32%, mixed 4% and 1% other/unavailable		

### Key results




\*Cardiovascular Core Lab at Morristown Medical Center  
NYHA: New York Heart Association; STS: Society for Thoracic Surgeons; MR: mitral regurgitation; MV: mitral valve



### Outcomes at 1 year:

- High survival and low event rates
- Low rate of heart failure hospitalisation
- Core lab-adjudicated sustained MR  $\leq 1+$  durability with 83% patients at MR  $\leq 1+$
- Significant and sustained clinical, functional and quality-of-life improvements
- Positive outcomes in both FMR and DMR patients



Graphs show unpaired data.  $\Delta$  and p-values calculated from paired analysis. <sup>a</sup>Wilcoxon signed rank test. <sup>b</sup>Student's t-test

NYHA: New York Heart Association; KCCQ: Kansas City Cardiomyopathy Questionnaire; EQ5D: EuroQol 5 Dimensions Health Questionnaire

## Conclusion

- In the ongoing MiCLASP post-market study at 1 year, the PASCAL system demonstrated favourable safety and sustained MR reduction accompanied by significant symptomatic and quality-of-life improvements.

See what we're making possible at [Edwards.com/PASCAL](https://www.edwards.com/PASCAL)

MR: mitral regurgitation; FMR: functional mitral regurgitation; DMR: degenerative mitral regurgitation

<sup>1</sup>Lurz P. One-year outcomes for transcatheter mitral repair from the MiCLASP study. PCR London Valves 2022

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](https://eifu.edwards.com) where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--EU-5408 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](https://www.edwards.com)